Abstract Library

#3526 Neurofibromatosis type 1 in combination with Pheochromocytoma (clinical case)

Introduction: Neurofibromatosis type 1 (NF-1) is a rare disease with characteristic pathological changes of the skin and nervous system, often in combination with abnormalities of other organs and systems. Endocrine neoplasms such as pheochromocytoma/paraganglioma, gastroenteropancreatic neuroendocrine tumors, thyroid tumors, and adrenal tumors, can also be rarely associated with NF-1.

Conference:

Presenting Author: Motrenko A

Authors: Motrenko A, Britvin T, Ilovayskaya I, Gurevich L,

Keywords: Neurofibromatos, pheochromocytoma, metanerins,

#2156 Two Cases Synchronous Atypical Parathyroid Adenomas and Papillary Thyroid Carcinoma

Introduction: A literature review revealed a prevalence of approximately 3% of nonmedullary thyroid cancer, which was found in patients operated on for primary hyperparathyroidism (pHPT). Papillary thyroid carcinomas(PTC) is a malignant epithelial tumour. PTC represent up to 87% of all thyroid carcinomas. Atypical parathyroid adenoma(APA) are a subset of parathyroid neoplasms that exhibit some of the features of parathyroid carcinoma but lack unequivocal invasive growth. APA represents about 0,5-4% of cases of pHPT. As a group, they may be considered tumors of uncertain malignant potential.

Conference: 15th Annual ENETSConcerence (2018)

Presenting Author:

Authors: Voronkova I, Mokrysheva N, Lapshina A, Gurevich L, Britvin T,

Keywords: papillary thyroid carcinomas, atypical parathyroid adenoma, primary hyperparathyroidism,

#1641 Somatostatin Receptor Expression in Adrenocortical Carcinoma

Introduction: Adrenocortical carcinoma (ACC) is an uncommon neoplasm with an estimated annual incidence of 0.5-2 cases per million population. Surgery of the adrenal tumor is the major treatment. When complete tumor removal is not possible, or in case of recurrence, medical treatment with O,p’DDD(mitotane) is recommended. The treatment of ACC is currently based on the mitotane partial responses have been described in 19-34% of cases, and there are single reports of complete responses.The discovery of somatostatin (SST) and the identification of stable SST analogs with a longer half-life have raised new hopes for the treatment of endocrine tumors.

Conference: 14th Annual ENETSConcerence (2017)

Presenting Author:

Authors: Voronkova I, Gurevich L, Kazanceva I, Krivosheev A, Britvin T,

Keywords: Adrenocortical carcinoma, Somatostatin receptor, Immunohistochemistry,

#1266 Three Cases of Ectopic Adrenocorticotropic Hormone Syndrome Due to Medullary Thyroid Carcinoma

Introduction: Сushing's syndrome (CS) in medullar thyroid carcinoma (MTC) is rare. Among patients with MTC 0,7 % developed ectopic ACTH-syndrome (EAS). EAS due to MTS occurs in 2,2-8% of cases.

Conference: 13th Annual ENETSConcerence (2016)

Presenting Author:

Authors: Gurevich L, Marova , Voronkova I, Britvin T, Afanasyeva Z,

Keywords: cushing's syndrome, medullary thyroid carcinoma ,

#827 Neuroendocrine Tumors of the Pancreas Grade 2 with Ki-67 Index More Than 5% and with Expression Cytokeratin 19 are the Risk Group of Rapid Progression

Introduction: Cytokeratin 19 (CK19) is the marker of pluripotent cells of the epithelium of the pancreatic ducts, which is not detected in differentiated endocrine cells. Our experience shows that many patients with neuroendocrine tumors of the pancreas (pNET) G2 have a rapid progression of the disease a few years after diagnosis, and metastases are found most commonly in the liver.

Conference: 11th Annual ENETSConcerence (2014)

Presenting Author:

Authors: Gurevich L, Korsakova N, Kazantseva I, Egorov A, Britvin T,

Keywords: pancreas, neuroendocrine tumors, risk factors, Ki-67, cytokeratin 19,